??-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

EeMei
2021-06-30

In the first half of the year, these 11 biomedical companies invested by Hillhouse have officially IPO

2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。公开资料显示，2021年以来，已经有11家高瓴投资的生物医药

In the first half of the year, these 11 biomedical companies invested by Hillhouse have officially IPO

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":153914555,"tweetId":"153914555","gmtCreate":1625004492477,"gmtModify":1703849749154,"author":{"id":4087745047715700,"idStr":"4087745047715700","authorId":4087745047715700,"authorIdStr":"4087745047715700","name":"EeMei","avatar":"https://static.tigerbbs.com/ef8409d8ad4dd460f4ff6b821735444f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>??</body></html>","htmlText":"<html><head></head><body>??</body></html>","text":"??","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/153914555","repostId":1102942162,"repostType":4,"repost":{"id":"1102942162","kind":"news","pubTimestamp":1624972114,"share":"https://ttm.financial/m/news/1102942162?lang=en_US&edition=fundamental","pubTime":"2021-06-29 21:08","market":"us","language":"zh","title":"In the first half of the year, these 11 biomedical companies invested by Hillhouse have officially IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1102942162","media":"医药观澜","summary":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药","content":"In 2021, Hillhouse's IPO direction will focus on a new generation of innovative drugs for gene therapy and cell therapy. In terms of the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and early stages are more favored.Public information shows that since 2021, 11 biopharmaceutical companies invested by Hillhouse have officially IPO on different stock exchanges. Looking at the 11 IPO projects, they are all companies driven by technological innovation. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases, etc. This article will share the basic information of these 7 companies for readers' reference only.1. Keji PharmaceuticalResearch area: Cell therapyKeji Pharmaceuticals is a clinical-stage biomedical company focusing on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based new tumor-associated antigens, and have been carefully designed and optimized to reduce the common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has established a research pipeline containing 11 candidate products, and 6 are in the clinical development stage. Among them, the BCMA targeted CAR-T therapy CT053 has been granted the Regenerative Medicine Advanced Therapy Designation (RMAT) and Orphan Drug Designation by the FDA, the Priority Drug Designation (PRIME) and Orphan Drug Designation by the European Medicines Agency (EMA), and China A breakthrough therapeutic variety granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2-targeted CAR-T products, autologous CAR-T product candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), etc.2. Century TherapeuticsResearch area: Cell therapyCentury Therapeutics is committed to leveraging the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSC) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thus providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical research and development projects include a variety of CAR-iT and CAR-iNK cell products derived from induced pluripotent stem cells, which are planned to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.3. Lyell ImmunopharmaResearch area: Cell therapyLyell Immunopharma aims to develop T cell therapies for solid tumors with \"cure\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on Nasdaq. Lyell believes that T cell therapy faces two major obstacles in the treatment of solid tumors: First, the exhaustion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not long-lasting enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting the ROR1 antigen. The product adds a safety switch based on the optimized epidermal growth factor receptor (EGFR) and is planned to be developed for the treatment of expressing ROR1. Non-small cell lung cancer, triple-negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also collaborating with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.4. Talaris TherapeuticsResearch area: Cell therapyTalaris Therapeutics is committed to developing treatments through one-time cell therapy to permanently solve the problem that organ transplant patients need to receive long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of taking immunosuppressive drugs for a long time have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative therapy to improve the body's immune tolerance. Her research found that there is a kind of facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are produced. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, the research cell therapy FCR001 developed by Talaris has entered the late clinical trial stage, and it is planned to be developed to treat patients who have previously received kidney transplantation from living donors and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and Regenerative Medicine Advanced Therapy Designation (RMAT).5. Zhaoke OphthalmologyResearch areas: Innovative ophthalmic drugsZhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensing introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates (including 13 innovative drugs and 12 generic drugs), covering most of the major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\">It is reported that the initial research and development of Zhaoke Ophthalmology focuses on five major ophthalmic indications in China, namely dry eye syndrome (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma. The development of many ophthalmic diseases is divided into multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop a variety of drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.6. Design TherapeuticsResearch area: Autoimmune diseasesDesign Therapeutics, which develops drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on Nasdaq in March 2021. Nucleotide repeat diseases are a kind of hereditary diseases caused by the repeated amplification of certain short sequences of genes. Depending on their location, repetitive sequences may lead to changes in gene expression regulation or produce toxic gene products, which are considered to be important factors in causing degenerative diseases.<img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targets an indication for patients with Friedreich's ataxia (FA). FA is the most common type of hereditary ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targets an indication for myotonic dystrophy type-1 (DM1). DM1 is a single-gene, autosomal dominant, progressive neuromuscular disease caused by mutations in the DMPK gene that affect skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological function.7. Instil BioResearch area: Cell therapyInstil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, listed on the Nasdaq in March 2021. According to information on the official website of Instil Bio, the company's fastest research product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is already in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of indications such as cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: dental devices), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnostics) It has also been IPO this year. Due to space limitations, this article will not introduce them one by one.From the current point of view, Hillhouse's IPO direction in 2021 will focus on a new generation of innovative drugs for gene therapy and cell therapy. In terms of the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and early stages are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-time supporter of these companies.It is expected that with the help of capital, these enterprises can launch innovative products on the market as soon as possible to benefit human health.","source":"lsy1593326364857","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In the first half of the year, these 11 biomedical companies invested by Hillhouse have officially IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn the first half of the year, these 11 biomedical companies invested by Hillhouse have officially IPO\n</h2>\n<h4 class=\"meta\">\n\n医药观澜2021-06-29 21:08\n\n</h4>\n</header>\n<article>\nIn 2021, Hillhouse's IPO direction will focus on a new generation of innovative drugs for gene therapy and cell therapy. In terms of the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and early stages are more favored.Public information shows that since 2021, 11 biopharmaceutical companies invested by Hillhouse have officially IPO on different stock exchanges. Looking at the 11 IPO projects, they are all companies driven by technological innovation. Among them, there are 7 cutting-edge companies focusing on innovative therapies. Their research fields include cell therapy, innovative ophthalmic drugs, autoimmune diseases, etc. This article will share the basic information of these 7 companies for readers' reference only.1. Keji PharmaceuticalResearch area: Cell therapyKeji Pharmaceuticals is a clinical-stage biomedical company focusing on innovative cell therapies for the treatment of solid tumors and hematological malignancies. Since its establishment, Keji Pharmaceutical has been developing innovative and differentiated innovative products focusing on CAR-T cell therapy. Public information shows that the company's CAR-T product candidates are evidence-based new tumor-associated antigens, and have been carefully designed and optimized to reduce the common side effects of existing CAR-T therapies. In June 2021, Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/0718a4dbb06171c8ac471c5b084ded19\" tg-width=\"345\" tg-height=\"129\" referrerpolicy=\"no-referrer\">It is reported that Keji Pharmaceutical has established a research pipeline containing 11 candidate products, and 6 are in the clinical development stage. Among them, the BCMA targeted CAR-T therapy CT053 has been granted the Regenerative Medicine Advanced Therapy Designation (RMAT) and Orphan Drug Designation by the FDA, the Priority Drug Designation (PRIME) and Orphan Drug Designation by the European Medicines Agency (EMA), and China A breakthrough therapeutic variety granted by the National Food and Drug Administration (NMPA). In addition, the company's products under development also include CLDN18.2-targeted CAR-T products, autologous CAR-T product candidates targeting phosphatidylinositol proteoglycan-3 (GPC3), etc.2. Century TherapeuticsResearch area: Cell therapyCentury Therapeutics is committed to leveraging the potential of adult stem cells to develop cell therapy products for the treatment of cancer to overcome the limitations of first-generation cell therapies. The company's technology platform relies on induced pluripotent stem cells (iPSC) with unlimited self-renewal capabilities. The technology uses multiple rounds of cell engineering to create a master cell bank that can expand and differentiate into immune effector cells, thus providing a large number of allogeneic, homologous therapeutic products. In June 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/ebdab209c719a1865a19e7329210a703\" tg-width=\"570\" tg-height=\"190\" referrerpolicy=\"no-referrer\">According to reports, Century Therapeutics' preclinical research and development projects include a variety of CAR-iT and CAR-iNK cell products derived from induced pluripotent stem cells, which are planned to be developed for the treatment of hematological cancers and solid tumors. Among them, the drug candidate CNTY-101 is an allogeneic, iPSC-derived CAR-iNK cell therapy intended to be developed for the treatment of relapsed/refractory B-cell lymphoma. The drug candidate CNTY-103 is a CAR-iNK candidate targeting CD133/EGFR and is intended for the treatment of recurrent glioblastoma (GBM). In addition, the company is developing drug candidates for the treatment of relapsed/refractory B-cell lymphoma, acute myeloid leukemia (AML) and other diseases.3. Lyell ImmunopharmaResearch area: Cell therapyLyell Immunopharma aims to develop T cell therapies for solid tumors with \"cure\" potential by \"reprogramming\" T cells. In June 2021, the company officially landed on Nasdaq. Lyell believes that T cell therapy faces two major obstacles in the treatment of solid tumors: First, the exhaustion of T cells causes it to lose its function of killing tumor cells; Second, the stem cell characteristics of T cells are not long-lasting enough, resulting in limited continuous proliferation and renewal ability of T cell therapy. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms Gen-R and Epi-R to address these barriers to develop innovative therapies.<img src=\"https://static.tigerbbs.com/156517955166f0a82d8bd8c0e03602f3\" tg-width=\"200\" tg-height=\"200\" referrerpolicy=\"no-referrer\">According to reports, LYL797 developed by Lyell is a CAR-T therapy under development targeting the ROR1 antigen. The product adds a safety switch based on the optimized epidermal growth factor receptor (EGFR) and is planned to be developed for the treatment of expressing ROR1. Non-small cell lung cancer, triple-negative breast cancer and other cancers. Another product candidate, LYL845, is an autologous tumor infiltrating lymphocyte (TIL) therapy that is expected to treat a variety of solid tumors. In addition, the company is also collaborating with GlaxoSmithKline (GSK) to develop TCR-T cell therapies targeting NY-ESO-1.4. Talaris TherapeuticsResearch area: Cell therapyTalaris Therapeutics is committed to developing treatments through one-time cell therapy to permanently solve the problem that organ transplant patients need to receive long-term immunosuppressive therapy. In May 2021, the company went public on the Nasdaq.<img src=\"https://static.tigerbbs.com/94382e61a569a56d90efdf9e700b4aa4\" tg-width=\"640\" tg-height=\"334\" referrerpolicy=\"no-referrer\">The side effects of taking immunosuppressive drugs for a long time have made Dr. Suzanne Ildstad, the founder of Talaris, determined to develop an innovative therapy to improve the body's immune tolerance. Her research found that there is a kind of facilitating cells in the bone marrow. Unlike stem cells, these cells can help stem cells transplanted into the host migrate into the bone marrow, where immune cells and other blood cells are produced. In addition, promoting cells can also enhance the host's immune tolerance and reduce the risk of graft-versus-host disease (GVHD). According to reports, the research cell therapy FCR001 developed by Talaris has entered the late clinical trial stage, and it is planned to be developed to treat patients who have previously received kidney transplantation from living donors and patients with severe autoimmune diseases. Previously, the FDA has granted FCR001 orphan drug designation and Regenerative Medicine Advanced Therapy Designation (RMAT).5. Zhaoke OphthalmologyResearch areas: Innovative ophthalmic drugsZhaoke Ophthalmology is committed to the discovery, development and commercialization of ophthalmic therapies. Through self-development or licensing introduction, Zhaoke Ophthalmology has established a comprehensive ophthalmic drug pipeline containing 25 drug candidates (including 13 innovative drugs and 12 generic drugs), covering most of the major ophthalmic indications affecting the anterior and posterior segments of the eye. In April 2021, Zhaoke Ophthalmology was officially listed on the Hong Kong Stock Exchange.<img src=\"https://static.tigerbbs.com/d46d549a89fd16eba51aeeef02ba7eab\" tg-width=\"640\" tg-height=\"177\" referrerpolicy=\"no-referrer\">It is reported that the initial research and development of Zhaoke Ophthalmology focuses on five major ophthalmic indications in China, namely dry eye syndrome (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma. The development of many ophthalmic diseases is divided into multiple stages due to the presence of multiple pathological processes. Therefore, most ophthalmic diseases are heterogeneous diseases. For different ophthalmic indications, Zhaoke Ophthalmology's development strategy is to choose to develop a variety of drug candidates with different mechanisms of action, hoping to bring flexible treatment options to patients through monotherapy or combination administration.6. Design TherapeuticsResearch area: Autoimmune diseasesDesign Therapeutics, which develops drugs to treat severe degenerative diseases caused by nucleotide repeat amplification, went public on Nasdaq in March 2021. Nucleotide repeat diseases are a kind of hereditary diseases caused by the repeated amplification of certain short sequences of genes. Depending on their location, repetitive sequences may lead to changes in gene expression regulation or produce toxic gene products, which are considered to be important factors in causing degenerative diseases.<img src=\"https://static.tigerbbs.com/bea91a3c2d92095a7a6f6b3a4d4c8a53\" tg-width=\"640\" tg-height=\"187\" referrerpolicy=\"no-referrer\">According to the official website of Design Therapeutics, the company currently has two major research projects. One of the research projects targets an indication for patients with Friedreich's ataxia (FA). FA is the most common type of hereditary ataxia. Due to mutations in the FXN gene, the production of frataxin is restricted, which in turn leads to various debilitating symptoms and complications. Another research project targets an indication for myotonic dystrophy type-1 (DM1). DM1 is a single-gene, autosomal dominant, progressive neuromuscular disease caused by mutations in the DMPK gene that affect skeletal muscle, heart, brain, and other organs. The main features of the disease include muscle weakness, myotonia (slow muscle relaxation), and early cataracts. Furthermore, affected individuals often experience arrhythmias and changes in neuropsychological function.7. Instil BioResearch area: Cell therapyInstil Bio, a global clinical-stage cell therapy company dedicated to the development of tumor-infiltrating lymphocyte therapies for the treatment of cancer, listed on the Nasdaq in March 2021. According to information on the official website of Instil Bio, the company's fastest research product under development is ITIL-168, and its clinical trial for the treatment of advanced melanoma is already in the phase 1 clinical trial stage. In addition, ITIL-168 is also intended to be developed for the treatment of indications such as cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC) and cervical cancer.<img src=\"https://static.tigerbbs.com/10d035fb5dbb022afd385010f2bad15c\" tg-width=\"575\" tg-height=\"269\" referrerpolicy=\"no-referrer\">In addition to the above-mentioned companies, Hillhouse invested in Nanotechnology (research field: nanospheres), Times Angel (research field: dental devices), Xintong Medical (research field: heart valves), and Beikang Medical (research field: in vitro diagnostics) It has also been IPO this year. Due to space limitations, this article will not introduce them one by one.From the current point of view, Hillhouse's IPO direction in 2021 will focus on a new generation of innovative drugs for gene therapy and cell therapy. In terms of the types of enterprises they invest in, science and technology enterprises with strong innovative R&D capabilities and early stages are more favored. For most of these projects, Hillhouse has made multiple rounds of investment and is a long-time supporter of these companies.It is expected that with the help of capital, these enterprises can launch innovative products on the market as soon as possible to benefit human health.\n<div class=\"bt-text\">\n\n\n source：<a href=\"https://wallstreetcn.com/articles/3634131\">医药观澜</a>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/890dd2dfb205aa8aa1d140672304b3c8","relate_stocks":{"IPSC":"Century Therapeutics, Inc.","02171":"科济药业-B"},"source_url":"https://wallstreetcn.com/articles/3634131","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102942162","content_text":"2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。\n公开资料显示，2021年以来，已经有11家高瓴投资的生物医药企业，在不同的证券交易所正式IPO。纵观11个IPO项目，均为科技创新驱动型公司。其中，有7家专注创新疗法的新锐公司，他们的研究领域包括细胞治疗、眼科创新药物、自身免疫疾病等等。本文将分享这7家公司的基本信息，仅供读者参阅。\n1、科济药业\n研究领域：细胞治疗\n科济药业是一家临床阶段的生物医药公司，专注于治疗实体瘤和血液恶性肿瘤的创新细胞疗法。自成立以来，科济药业一直在研发以CAR-T细胞疗法为重点的创新及差异化创新产品。公开资料显示，该公司CAR-T候选产品循证新型肿瘤相关抗原，并经过精心设计和优化，以减少现有CAR-T疗法常见的副作用。2021年6月，科济药业正式在港交所挂牌。据悉，科济药业现已建立一条包含11款候选产品的在研管线，且6款正处于临床开发阶段。其中，BCMA靶向CAR-T疗法CT053曾获FDA授予的再生医学先进疗法认定（RMAT）和孤儿药资格，欧洲药品管理局（EMA）授予的优先药物资格（PRIME）和孤儿药资格，以及中国国家药监局（NMPA）授予的突破性治疗品种。此外，该公司的在研产品还包括CLDN18.2靶向CAR-T产品、靶向磷脂酰肌醇蛋白聚糖-3（GPC3）的自体CAR-T候选产品等等。\n2、Century Therapeutics\n研究领域：细胞治疗\nCentury Therapeutics致力于利用成体干细胞的潜力，开发治疗癌症的细胞疗法产品，以克服第一代细胞疗法的局限性。该公司的技术平台依托于具有无限自我更新能力的诱导多能干细胞（iPSC）。该技术通过多轮细胞工程来创建主细胞库，这些细胞可扩展和分化成免疫效应细胞，从而提供大量同种异体、同源的治疗产品。2021年6月，该公司在纳斯达克上市。据介绍，Century Therapeutics公司的临床前研发项目包括多种诱导多能干细胞衍生的CAR-iT和CAR-iNK细胞产品，拟开发用于治疗血液癌症和实体瘤。其中，候选药物CNTY-101是一种同种异体、iPSC衍生的CAR-iNK细胞疗法，拟开发用于治疗复发性/难治性B细胞淋巴瘤。候选药物CNTY-103为靶向CD133/EGFR的CAR-iNK候选物，拟用于治疗复发性胶质母细胞瘤（GBM）。此外，该公司还在开发用于治疗复发性/难治性B细胞淋巴瘤、急性髓系白血病（AML）等疾病的候选药物。\n3、Lyell Immunopharma\n研究领域：细胞治疗\nLyell Immunopharma旨在通过对T细胞进行“重编程”（reprogramming），开发具有“治愈”潜力的实体瘤T细胞疗法。2021年6月，该公司正式登陆纳斯达克。Lyell公司认为，T细胞疗法在治疗实体瘤治疗方面主要面临两大障碍：一是，T细胞耗竭导致其失去杀伤肿瘤细胞的功能；二是，T细胞的干细胞特征不够持久，导致T细胞疗法的持续增殖和更新能力有限。Lyell公司正在应用其专有的离体遗传和表观遗传重编程技术平台Gen-R和Epi-R来解决这些障碍，以开发创新疗法。据介绍，Lyell公司开发的LYL797是一款靶向ROR1抗原的在研CAR-T疗法，该产品添加了一个基于优化的表皮生长因子受体（EGFR）的安全开关，拟开发用于治疗表达ROR1的非小细胞肺癌、三阴性乳腺癌等癌症。另一款候选产品LYL845是一种自体肿瘤浸润淋巴细胞（TIL）疗法，有望治疗多种实体瘤。此外，该公司还在与葛兰素史克（GSK）合作开发靶向NY-ESO-1的TCR-T细胞疗法。\n4、Talaris Therapeutics\n研究领域：细胞治疗\nTalaris Therapeutics致力于开发通过一次性细胞疗法的治疗，永久性解决器官移植患者需要接受长期免疫抑制疗法的难题。2021年5月，该公司在纳斯达克上市。长期服用免疫抑制药物的副作用，让Talaris公司的创始人Suzanne Ildstad博士决心开发一种提高机体免疫耐受力的创新疗法。她的研究发现骨髓中存在一种促进细胞（facilitating cell），这些细胞与干细胞不同，它们能够帮助移植到宿主体内的干细胞迁移到骨髓中，在那里生成免疫细胞和其它血细胞。此外，促进细胞还能够增强宿主的免疫耐受能力，降低移植物抗宿主病（GVHD）产生的风险。据介绍，Talaris公司开发的在研细胞疗法FCR001已进入后期临床试验阶段，拟开发治疗以前接受活体供体肾脏移植的患者、重度自身免疫性疾病患者等。此前，FDA已授予FCR001孤儿药资格和再生医学先进疗法认定（RMAT）。\n5、兆科眼科\n研究领域：眼科创新药\n兆科眼科致力于发现、开发及商业化眼科疗法。通过自主开发或许可引进，兆科眼科已建立起一条包含25种候选药物（包含13种创新药和12种仿制药）的全面眼科药物管线，涵盖影响眼前节及眼后节的多数主要眼科适应症。2021年4月，兆科眼科正式在港交所上市。\n\n据悉，兆科眼科初步研发重心聚焦中国五大眼科适应症上，即干眼症(DED)、湿性老年黄斑部病变(wAMD)、糖尿病黄斑水肿(DME)、近视眼以及青光眼。由于存在多种病理过程，许多眼科疾病的发展分多个阶段。因此，大部分眼科疾病属于异质性疾病。对于不同的眼科适应症，兆科眼科的开发策略是选择开发具有不同作用机制的多种候选药物，希望通过单一疗法或联合给药，给患者带来灵活的治疗选择。\n6、Design Therapeutics\n研究领域：自身免疫疾病\nDesign Therapeutics致力于开发治疗由核苷酸重复序列扩增引起的严重退行性疾病的药物，该公司于2021年3月在纳斯达克上市。核苷酸重复序列疾病是由基因的某些短序列重复扩增而引起的一类遗传性疾病。根据其所处位置，重复序列可能会导致基因表达调控的改变或产生有毒的基因产物，它们被认为是造成退行性疾病的重要因素。\n根据Design Therapeutics官网，该公司目前有两个主要研究项目。其中一个研究项目针对的适应症为Friedreich共济失调（Friedreich’s ataxia，FA）患者。FA是一种最常见的遗传性共济失调类型，由于FXN基因的突变，限制了共济蛋白（frataxin）的产生，进而导致各种衰弱的症状和并发症。另一个研究项目针对的适应症为强直性肌营养不良1型(myotonic dystrophy type-1，DM1)。DM1是一种单基因、常染色体显性遗传、进行性神经肌肉疾病，由DMPK基因突变引起，影响骨骼肌、心脏、大脑和其他器官。该病的主要特征包括肌肉无力、肌强直（肌肉松弛缓慢）和早期白内障。此外，受影响的个体经常会出现心律失常和神经心理功能的变化。\n7、Instil Bio\n研究领域：细胞治疗\nInstil Bio是一家全球性的临床阶段细胞疗法公司，致力于开发治疗癌症的肿瘤浸润淋巴细胞疗法，该公司于2021年3月在纳斯达克上市。Instil Bio官网信息显示，该公司研究进度最快的在研产品为ITIL-168，其治疗晚期黑色素瘤的临床试验已处于1期临床试验阶段。此外，ITIL-168还拟被开发用于治疗皮肤鳞状细胞癌（CSCC）、非小细胞肺癌（NSCLC）和宫颈癌等适应症。除了上述企业，高瓴投资的纳微科技（研究领域：纳米微球）、时代天使（研究领域：口腔器械）、心通医疗（研究领域：心脏瓣膜）、贝康医疗（研究领域：体外诊断）也已在今年IPO。限于篇幅，本文不再一一介绍。\n就目前来看，2021年高瓴的IPO方向以新一代基因治疗、细胞疗法的创新药为主。就其投资的企业类型来看，创新研发能力强、处于早期阶段的科创企业更受青睐。对于其中大部分项目，高瓴都进行了多轮投资，是这些公司的长期支持者。\n期待这些企业在资本的助力下，可以早日将创新产品推出市场，造福人类健康。","news_type":1,"symbols_score_info":{"02171":0.9,"IPSC":0.9}},"isVote":1,"tweetType":1,"viewCount":2854,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}